Astria Therapeutics Executive Compensation (FY24)
ATXS · Executive and director compensation, fiscal 2023 to 2024
Chief executive, fiscal 2024 ◇ Jill Milne | Latest say-on-pay support = June 11, 2025 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Astria Therapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 4, 2026Latest filing (8-K): June 12, 2025
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
94 figures on this page: 92 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jill Milne: $2,955,504 → $6,604,416 (123.5% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Astria Therapeutics' chief executive and what were they paid?
Total compensation for Jill Milne, President and Chief Executive Officer, came to $6,604,416 in fiscal 2024. Compared with the $2,955,504 reported for fiscal 2023, Milne's total was 123.5% higher.
What was Astria Therapeutics' say-on-pay result?
Shareholders recorded 86.8% support for the say-on-pay proposal at the meeting held June 11, 2025 for fiscal 2024.
Which companies are in Astria Therapeutics' peer group?
Companies named in the disclosed peer group include Adicet Bio, Inc., Aerovate Therapeutics, Inc., Annexon Biosciences, AVROBIO, Inc. and Cue Biopharma, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jill Milne President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Morabito Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Benjamin Harshbarger Chief Legal Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jill Milne President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Morabito Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Benjamin Harshbarger Chief Legal Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jill Milne | Option | ◇ | — | ◇ | 2/7/2034 |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Option | ◇ | — | ◇ | 2/29/2032 | |
| Option | ◇ | — | ◇ | 3/31/2031 | |
| Benjamin Harshbarger | Option | ◇ | — | ◇ | 2/7/2034 |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Option | ◇ | — | ◇ | 2/29/2032 | |
| Option | ◇ | — | ◇ | 3/31/2031 | |
| Option | ◇ | — | ◇ | 6/7/2031 | |
| Christopher Morabito | Option | ◇ | — | ◇ | 2/7/2034 |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Option | ◇ | — | ◇ | 7/31/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Sunil Agarwal | ◇ | — | ◇ | — | — | — | ◇ |
Kenneth Bate Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Gregg Lapointe | ◇ | — | ◇ | — | — | — | ◇ |
Jonathan Violin | ◇ | — | ◇ | — | — | — | ◇ |
Michael Kishbauch | ◇ | — | ◇ | — | — | — | ◇ |
Joanne Beck | ◇ | — | ◇ | — | — | — | ◇ |
Fred Callori | ◇ | — | ◇ | — | — | — | ◇ |
Hugh Cole | ◇ | — | ◇ | — | — | — | ◇ |
Jill C. Milne served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Adicet Bio, Inc. ACET
- Aerovate Therapeutics, Inc. symbol not shown
- Annexon Biosciences ANNX
- AVROBIO, Inc. symbol not shown
- Cue Biopharma, Inc. CUE
- Edgewise Therapeutics, Inc. EWTX
- Foghorn Therapeutics, Inc. FHTX
- Inozyme Pharma, Inc. INZY
- Larimar Therapeutics, Inc. LRMR
- Ocugen, Inc. OCGN
- Rallybio RLYB
- Reneo Pharmaceuticals, Inc. symbol not shown
- Savara, Inc. SVRA
- Third Harmonic Bio THRD
- Vigil Neuroscience, Inc. VIGL
- Viridian Therapeutics, Inc. VRDN
- Werewolf Therapeutics, Inc. HOWL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | June 11, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Jill Milne (President and Chief Executive Officer), FY2024 total compensation $6,604,416 (base salary $637,868) [exec_comp, SEC accession 0001104659-25-040180, filed 2025-04-28]What this page does not include
Everything above is a fact Astria Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Astria Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
94 figures on this page: 92 cited to the filing that reported them, 2 calculated from figures it prints.
92 cited to the filing
2 calculated from the filing
Documents cited
- 0001104659-25-058887Proposal 4 . The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers.
- 0001104659-25-040180
- 0001104659-24-069064Proposal 4 . The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Astria Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/ATXS (accessed 2026).
Short form: data: Velarion
The Astria Therapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Astria Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Astria Therapeutics discloses
The companies named in ATXS's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}